Na+-K+-Cl- cotransporter in rat focal cerebral ischemia.
In cultured neurons, the authors previously demonstrated that the Na+-K+-Cl- cotransporter is significantly stimulated by elevated extracellular potassium and glutamate, which are important factors in cerebral ischemic damage. These findings led the authors to hypothesize that stimulation of the cotransporter after ischemia might result in Na+, K+, and Cl- influx, and might contribute to neuron damage. In the current study, the authors investigated such a role of the Na+-K+-Cl- cotransporter in focal cerebral ischemia. Cerebral ischemia was induced by 2-hour occlusion of the left middle cerebral artery (MCA) and 24-hour reperfusion in male spontaneously hypertensive rats (SHRs). Immunocytochemical staining and immunoblotting revealed an up-regulation of expression of the cotransporter protein in neurons in cortex at 24 hours of reperfusion. Artificial cerebral spinal fluid (aCSF) or 100 micromol/L bumetanide (a cotransporter inhibitor) in aCSF were continuously microdialyzed through a microdialysis probe into left cortices throughout 2-hour MCA occlusion and 24-hour reperfusion. Compared with the aCSF-treated group, infarction volume was significantly reduced in the bumetanide-treated group (25%, P < 0.05). In addition, brain water content in the bumetanide-treated brains was decreased by 70% (P < 0.05). These results strongly suggest that the Na+-K+-Cl- cotransporter may play an important role in cerebral ischemic neuronal damage.
Yan
Y
Y
Department of Neurological Surgery, University of Wisconsin Medical School, Madison 53792, USA.
Dempsey
R J
RJ
Sun
D
D
D000818:Animals; D001253:Astrocytes / Q000737:chemistry; D001345:Autoradiography; D001923:Brain Chemistry; D001929:Brain Edema / Q000209:etiology / Q000517:prevention & control; D002034:Bumetanide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002352:Carrier Proteins / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D002540:Cerebral Cortex / Q000737:chemistry / Q000187:drug effects; D002544:Cerebral Infarction / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D003250:Constriction; D005904:Glial Fibrillary Acidic Protein / Q000032:analysis; D006973:Hypertension / Q000150:complications / Q000503:physiopathology; D015151:Immunoblotting; D007150:Immunohistochemistry; D002546:Ischemic Attack, Transient / Q000150:complications / Q000503:physiopathology*; D008297:Male; D017551:Microdialysis; D020768:Middle Cerebral Artery; D009474:Neurons / Q000737:chemistry; D010751:Phosphopyruvate Hydratase / Q000032:analysis; D051381:Rats; D011918:Rats, Inbred SHR; D015424:Reperfusion; D028021:Sodium-Potassium-Chloride Symporters; D014404:Tubulin / Q000032:analysis
D002352:Carrier Proteins; D005904:Glial Fibrillary Acidic Protein; D028021:Sodium-Potassium-Chloride Symporters; D014404:Tubulin; D002034:Bumetanide; D010751:Phosphopyruvate Hydratase